TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26976872
Drug: Echinocandins/L-AmB-based regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinocandins/L-AmB-based regimen
Study: 26977746
Drug: Nucleoside-Sparing Regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside-Sparing Regimens with Raltegravir and a Boosted Protease Inhibitor
Study: 26978384
Drug: Maternal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal blood lead level (BLL) > 50 µg/L
Study: 26978384
Drug: Children's blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children's blood lead level (BLL) > 50 µg/L
Study: 26978775
Drug: Disposable intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disposable intranasal mucosal atomization device (DIMAD)
Study: 26980473
Drug: Icotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (250 mg, three times daily)
Study: 26980480
Drug: PepCan 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PepCan 50 μg
Study: 26980480
Drug: PepCan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PepCan 100 μg
Study: 26981247
Drug: ONCOS-102 plus
Normalized name: ONCOS-102
DrugBank: ONCOS-102 (DB17274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONCOS-102 plus daily low-dose oral cyclophosphamide (CPO)
Study: 26984445
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg) administered intravenously every 21 days for 3 cycles
Study: 26984445
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg orally) as a positive control
Study: 26987488
Drug: Rivaroxaban administered
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban administered within 30 days of the index stroke for secondary prevention of stroke
Study: 26990620
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies measured every trimester and postpartum; IgG aPL levels significantly lower during the second and third trimesters compared to initial screening.
Study: 26990620
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies measured every trimester and postpartum; IgM aPL titers were negative in the majority of patients and decreased modestly during pregnancy.
Study: 26990620
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies measured every trimester and postpartum; changes in aPL levels or aPL status.
Study: 26990620
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant (LAC) presence.
Study: 26991823
Drug: Palbociclib 100
Normalized name: palbociclib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 100 mg once daily (3 weeks on/1 week off)
Study: 26991823
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg once daily (3 weeks on/1 week off)
Study: 26991823
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg plus letrozole 2.5 mg
Study: 26991823
Drug: Palbociclib 100
Normalized name: palbociclib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 100 mg
Study: 26993070
Drug: Acute hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hypoglycemia (2.8 mmol/L) during a hyperinsulinemic euglycemic-hypoglycemic glucose clamp after an overnight fast.
Study: 26993070
Drug: Healthy control
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy control subjects (n = 7) during acute hypoglycemia (2.8 mmol/L).
Study: 26993070
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with normal awareness of hypoglycemia (NAH) during acute hypoglycemia (2.8 mmol/L).
Study: 26993071
Drug: Model-based method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based method to estimate hepatic and extrahepatic insulin clearance
Study: 26993131
Drug: dHER2 immunotherapeutic
Normalized name: dHER2 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dHER2 immunotherapeutic (20, 100, 500 µg) combined with AS15
Study: 26993131
Drug: dHER2 immunotherapeutic
Normalized name: dHER2 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dHER2 immunotherapeutic (500 µg) with the most intense immunization schedule
Study: 26993266
Drug: Agalsidase β
Normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase β (1 mg/kg every 2 weeks)
Study: 26993869
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical stimulation at a current twice their motor threshold, at 1 Hz, for 5 minutes.
Study: 26998426
Drug: CT+G (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT+G (chemotherapy plus goserelin)
Study: 26998426
Drug: CT (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (chemotherapy only)
Study: 26999488
Drug: Antiangiogenic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic therapy
Study: 27001822
Drug: M-EDTA-EtOH lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-EDTA-EtOH lock solution administered once daily for 2 hours for a total of 7 doses.
Study: 27001822
Drug: M-EDTA-EtOH lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-EDTA-EtOH lock solution.
Study: 27003363
Drug: Pazopanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib plus CapeOx (capecitabine 850 mg/m2 bid, day 1-14; oxaliplatin 130 mg/m2, day 1; pazopanib 800 mg, day 1-21)
Study: 27004234
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid collection for antibody detection
Study: 27004241
Drug: Day-3 subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-3 subgroup (72-hour PPI infusion)
Study: 27004241
Drug: Day-2 subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-2 subgroup (one day early PPI infusion)
Study: 27004241
Drug: Endoscopic epinephrine-injection
Normalized name: epinephrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic epinephrine-injection monotherapy
Study: 27004241
Drug: Hypoalbuminemia <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoalbuminemia < 3.0 g/dL
Study: 27004241
Drug: Hypoalbuminemia <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoalbuminemia < 3.5 g/dL
Study: 27005892
Drug: Autologous cell
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cell therapy using CD133+ bone marrow-derived stem cells (BMDSCs) in conjunction with hormonal replacement therapy
Study: 27006491
Drug: Nilotinib therapy
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib therapy
Study: 27006492
Drug: TIL infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIL infusion followed by attenuated doses of IL2 administered in an intravenous, continuous decrescendo regimen
Study: 27006492
Drug: TIL infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TIL infusion followed by attenuated doses of IL2
Study: 27006728
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg weekly plus methotrexate for 24 weeks, continued for 104 weeks; total exposure 798.1 patient-years.
Study: 27006728
Drug: Conventional DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional DMARD (hydroxychloroquine or sulfasalazine) plus methotrexate for 24 weeks, followed by treatment modification.
Study: 27006728
Drug: Etanercept (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (continued or added) in the treatment regimen after week 24.
Study: 27007958
Drug: Incretin-based drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incretin-based drugs (DPP-4 inhibitors and GLP-1 analogues)
Study: 27007958
Drug: Oral antidiabetic-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic-drug combinations
Study: 27009059
Drug: Marizomib (MRZ)
Normalized name: Marizomib
DrugBank: Marizomib (DB11762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marizomib (MRZ) schedule A at 0.7 mg/m(2) infused over 10 minutes, administered to 32 patients.
Study: 27009059
Drug: Marizomib (MRZ)
Normalized name: Marizomib
DrugBank: Marizomib (DB11762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marizomib (MRZ) schedule B at 0.5 mg/m(2) infused over 2 hours, administered to 36 patients.
Study: 27009092
Drug: Adjuvant aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant aromatase inhibitors (AIs)
Study: 27010542
Drug: Primaquine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (single dose 0.25 mg base/kg)
Study: 27013512
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up without treatment of asymptomatic mono or mixed P. falciparum infections (24 participants)
Study: 27015562
Drug: Afatinib (ERBB1/2/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (ERBB1/2/4 inhibitor)
Study: 27015798
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (EART) based on lopinavir/r
Study: 27018703
Drug: Nitroglycerin Ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin Ointment
Study: 27019745
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy application
Study: 27019745
Drug: Mobile-sensing application
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile-sensing application promoting daily activities
Study: 27020111
Drug: Palliative Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative Radiation Therapy (RT) - 25 Gy in 5 daily intensity modulated RT fractions over 1 week
Study: 27021379
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mononuclear cell (ABMNC) therapy
Study: 27021538
Drug: 0.50% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50% chlorhexidine (CHX) gel applied using individual trays (3DS)
Study: 27021538
Drug: 0.50% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50% chlorhexidine (CHX) gel
Study: 27021967
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (mean dose 195.6 ± 154.8 mg/day)
Study: 27022067
Drug: Apatorsen (OGX-427)
Normalized name: Apatorsen
DrugBank: Apatorsen (DB06094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatorsen (OGX-427) administered i.v. weekly in 21-day cycles following 3 loading doses and over 5 dose levels (200-1000 mg)
Study: 27025160
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg/d on days 1-14) plus bortezomib (1.3 mg/m² intravenously on days 1, 4, 8, and 11)
Study: 27025399
Drug: Rise intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rise intervention (treatment education adherence intervention) consisting of 6-10 individual counseling sessions over 6 months.
Study: 27025608
Drug: VS-6063 (defactinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (defactinib, PF-04554878) 200 mg BID
Study: 27025608
Drug: VS-6063 (defactinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (defactinib, PF-04554878) 400 mg BID (RP2D)
Study: 27025608
Drug: VS-6063 (defactinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (defactinib, PF-04554878) 200-600 mg BID
Study: 27026379
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with portal vein thrombosis not treated with anticoagulant therapy
Study: 27029034
Drug: Sunitinib (50mg)
Normalized name: sunitinib 50 MG
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib (50mg) therapy for 3 cycles
Study: 27029034
Drug: Nephrectomy samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nephrectomy samples after sunitinib treatment
Study: 27029228
Drug: Bendamustine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine (90 mg/m² on days 1 and 2) plus Rituximab (375 mg/m² on day 1), every 4 weeks.
Study: 27030277
Drug: Intravitreal ziv-aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-aflibercept (1.25 mg/0.05 mL)
Study: 27030531
Drug: Diets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diets containing dietary pulses (median intake of 132 g/d or ∼1 serving/d)
Study: 27032057
Drug: Oral LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LNG
Study: 27032301
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus neoadjuvant chemotherapy (intravenous fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m², and bevacizumab 15 mg/kg during cycles 1-4; docetaxel 100 mg/m² and bevacizumab during cycles 5-8)
Study: 27032301
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (without bevacizumab)
Study: 27033958
Drug: Intravesical administration
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of hyaluronic acid and chondroitin sulfate (HA+CS)
Study: 27036160
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (3 mg/m² IV on day 1), all-trans retinoic acid (45 mg/m² orally on days 4-6 and 15 mg/m² orally on days 7-28), high-dose cytarabine (3 g/m²/12 h IV on days 1-3), mitoxantrone (12 mg/m² IV on days 2-3)
Study: 27036160
Drug: Patients responding
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation
Study: 27039387
Drug: Ixazomib 3
Normalized name: ixazomib 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 3 mg weekly
Study: 27039387
Drug: Ixazomib 4
Normalized name: ixazomib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 4 mg weekly
Study: 27039387
Drug: Ixazomib 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 5.5 mg (maximum tolerated dose)
Study: 27039986
Drug: Piperacillin-tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 4.5 g TID
Study: 27039986
Drug: Piperacillin-tazobactam 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 4.5 g BID
Study: 27040320
Drug: Pralatrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pralatrexate (10 to 30 mg/m²) + Bortezomib (1.3 mg/m²)
Study: 27042163
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg once daily (first dose 110 mg 1-4 h after surgery)
Study: 27042326
Drug: Augmentation index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation index (AIx@HR75) measurement
Study: 27043883
Drug: Red blood
Normalized name: Red blood cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red blood cell infusions
Study: 27043883
Drug: Plasma infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma infusions
Study: 27044576
Drug: tiotropium+olodaterol 5/5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium+olodaterol 5/5 µg with exercise training
Study: 27044576
Drug: tiotropium+olodaterol 5/5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium+olodaterol 5/5 µg without exercise training
Study: 27044576
Drug: tiotropium 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium 5 µg
Study: 27044938
Drug: LY2606368 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2606368 at 40 mg/m(2) (schedule 1)
Study: 27044938
Drug: LY2606368 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2606368 at 105 mg/m(2) (schedule 2)
Study: 27045164
Drug: Bosutinib therapy
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib therapy in AP CML patients
Study: 27045164
Drug: Bosutinib therapy
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib therapy in BP CML patients
Study: 27045862
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance index effect on betatrophin levels
Study: 27047630
Drug: Micro-focused ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-focused ultrasound with visualization with vertical vectoring treatment
Study: 27048835
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis ssp. lactis BB12 (BB12)
Study: 27048835
Drug: Control chewing
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control chewing tablet
Study: 27048911
Drug: Lurasidone 40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40-120 mg once daily
Study: 27049457
Drug: CUDC-907 once-daily
Normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUDC-907 once-daily (MTD 60 mg)
Study: 27049457
Drug: CUDC-907 twice-weekly
Normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUDC-907 twice-weekly (MTD 150 mg)
Study: 27049457
Drug: CUDC-907 three-times-weekly
Normalized name: PI3K/HDAC inhibitor CUDC-907
DrugBank: Fimepinostat (DB11891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUDC-907 three-times-weekly (MTD 150 mg)
Study: 27049457
Drug: CUDC-907 5/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUDC-907 5/2 dosing schedule (MTD 60 mg)
Study: 27049694
Drug: Women with
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with anaemia (Hb <120 g/l)
Study: 27052658
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg once a day) plus prednisone (5 mg twice a day)
Study: 27054297
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral glucose tolerance test (OGTT)
Study: 27055247
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT C1100 (50 mg/kg on Days 1 and 11, 50 mg/kg bid on Days 2 to 10)
Study: 27055247
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg bid on Days 2 to 10)
Study: 27055247
Drug: SMT C1100
Normalized name: ZINC OXIDE 2.94 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g / OCTINOXATE 7 g in 100 g TOPICAL CREAM [sMTS Dual HA SUN BLOCK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg tid on Days 2 to 10)
Study: 27055731
Drug: FOLFIRINOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX plus PF-04136309 (500 mg twice daily)
Study: 27056586
Drug: Reslizumab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reslizumab 0.3 mg/kg
Study: 27057326
Drug: Experimental formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental formula containing L. reuteri, GOS (5.50 g/L), and FOS (0.36 g/L)
Study: 27057326
Drug: Control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formula containing only L. reuteri
Study: 27058744
Drug: Intra-articular hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hypertonic dextrose injections (12.5% dextrose, 10 mL, four to six monthly injections)
Study: 27060341
Drug: Etravirine 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 5.2 mg/kg twice daily (maximum 200 mg twice daily) plus background antiretrovirals
Study: 27063977
Drug: OTX015 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015 at 80 mg/day (14 days on, 7 days off)
Study: 27063978
Drug: OTX015 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015 at 80 mg once a day (14 days on, 7 days off)
Study: 27063978
Drug: OTX015 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015 at 120 mg once a day
Study: 27063978
Drug: OTX015 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015 at 40 mg twice a day
Study: 27063978
Drug: OTX015 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTX015 at 80 mg once a day
Study: 27066336
Drug: Evolocumab self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab self-administered biweekly over 6 weeks (n=149)
Study: 27066336
Drug: Evolocumab self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab self-administered monthly over 12 weeks (n=164)